UNIVEST FINANCIAL Corp Sells 923 Shares of Regeneron Pharmaceuticals, Inc. $REGN

UNIVEST FINANCIAL Corp cut its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the 4th quarter, Holdings Channel reports. The fund owned 19,400 shares of the biopharmaceutical company’s stock after selling 923 shares during the quarter. Regeneron Pharmaceuticals comprises about 0.8% of UNIVEST FINANCIAL Corp’s holdings, making the stock its 27th largest position. UNIVEST FINANCIAL Corp’s holdings in Regeneron Pharmaceuticals were worth $14,974,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in REGN. WPG Advisers LLC raised its position in Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $31,000. Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. FNY Investment Advisers LLC bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $38,000. Finally, Torren Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $38,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.8%

Shares of REGN stock opened at $714.89 on Friday. The business has a 50-day moving average of $752.68 and a 200 day moving average of $740.44. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11. The stock has a market capitalization of $75.58 billion, a PE ratio of 17.42, a P/E/G ratio of 1.60 and a beta of 0.30.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period in the previous year, the firm earned $8.22 EPS. The business’s quarterly revenue was up 19.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.08 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on REGN shares. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Royal Bank Of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $779.00 to $762.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 30th. Oppenheimer reissued an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. TD Cowen boosted their price objective on shares of Regeneron Pharmaceuticals from $880.00 to $960.00 and gave the stock a “buy” rating in a report on Thursday, April 23rd. Finally, Piper Sandler started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They issued an “overweight” rating and a $875.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $826.59.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the company’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president directly owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,874 shares of company stock valued at $3,013,262 over the last three months. 6.97% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.